CoChat
Sign Up
Cited by 458Circadian rhythm and melatoninMetabolism, Diabetes, and CancerAdipose Tissue and Metabolism

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Muscle insulin sensitivity and glucose metabolism are controlled by the intrinsic muscle clock

Open access
Dyar, Kenneth A., Ciciliot, Stefano, Wright, Lauren E., Biensø, Rasmus S., Tagliazucchi, Guidantonio M., Patel, Vishal R., Forcato, Mattia, Paz, Marcia I.P., Gudiksen, Anders, Solagna, Francesca, Albiero, Mattia, Moretti, Irene, Eckel-Mahan, Kristin L., Baldi, Pierre, Sassone-Corsi, Paolo, Rizzuto, Rosario, Bicciato, Silvio, Pilegaard, Henriette, Blaauw, Bert, Schiaffino, Stefano·2014·Molecular Metabolism
DOI 10.1016/j.molmet.2013.10.005PMC PMC3929910
Open this paper in CoChat — free account

Abstract

Circadian rhythms control metabolism and energy homeostasis, but the role of the skeletal muscle clock has never been explored. We generated conditional and inducible mouse lines with muscle-specific ablation of the core clock gene Bmal1. Skeletal muscles from these mice showed impaired insulin-stimulated glucose uptake with reduced protein levels of GLUT4, the insulin-dependent glucose transporter, and TBC1D1, a Rab-GTPase involved in GLUT4 translocation. Pyruvate dehydrogenase (PDH) activity was also reduced due to altered expression of circadian genes Pdk4 and Pdp1, coding for PDH kinase and phosphatase, respectively. PDH inhibition leads to reduced glucose oxidation and diversion of glycolytic intermediates to alternative metabolic pathways, as revealed by metabolome analysis. The impaired glucose metabolism induced by muscle-specific Bmal1 knockout suggests that a major physiological role of the muscle clock is to prepare for the transition from the rest/fasting phase to the active/feeding phase, when glucose becomes the predominant fuel for skeletal muscle.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molmet.2013.10.005

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Characterization of skeletal muscle-specific Bmal1 knockout mice. (A) Survival curve of muscle-specific Bmal1 knockout mice (mKO) and control littermates (Ctrl) (n=12/group). (B) Body weight of control and mKO mice (mean±SEM; n=7–10/group/age; **p<0.01, 2-way ANOVA with the Bonferroni correction). (C) Weight of fast tibialis anterior (TA) and slow soleus (SOL) skeletal muscles from 5-month old mKO and control littermates (mean±SEM; n=36/group; ***p<0.001, Student's t-test). (D) Epididymal fat pad weight from 5-month old mKO and control littermates (mean±SEM; n=4/group). (E) Fiber type profile of slow soleus (SOL) and fast extensor digitorum longus (EDL) in transverse sections stained with anti-myosin antibodies specific for type-1/slow (blue), type-2A (green) and type 2B (red) myosin heavy chains. Type 2X fibers are unstained and appear black. Scale bar is 200 µμm. (F) Quantitation of the relative proportion of the different fiber types in SOL and EDL (mean±SEM, n=8 muscles per group with >90% of fibers measured; see methods; *p<0.05, Student's t-test). (G) Hematoxylin and eosin staining of transverse cryosections of SOL muscles from 26-month old mKO and control littermate. Scale bar is 50 µμm. (H) In vivo muscle force measurements performed on gastrocnemius muscles from 5-month old mKO and control littermates. Force normalized to muscle weight (mean±SEM, n=8–10 muscles per group; **p<0.01, ***p<0.001, 2-way ANOVA with Bonferroni correction). (I) Body weight of 7-month old inducible muscle-specific Bmal1 knockout mice (imKO, n=7) and control littermates (Ctrl, n=5) measured 5 months after tamoxifen injections (mean±SEM). (J) Weight of TA and SOL skeletal muscles from 7-month old imKO and control littermates measured 5 months after tamoxifen injections (mean±SEM; n=10–14/group). (K) In vivo muscle force measurements performed on gastrocnemius muscles from 7-month old imKO and control littermates 5 months after tamoxifen injection. Force normalized to muscle weight (mean±SEM, n=8–10 muscles per group).
Figure 1 Characterization of skeletal muscle-specific Bmal1 knockout mice. (A) Survival curve of muscle-specific Bmal1 knockout mice (mKO) and control littermates (Ctrl) (n=12/group). (B) Body weight of control and mKO mice (mean±SEM; n=7–10/group/age; **p<0.01, 2-way ANOVA with the Bonferroni correction). (C) Weight of fast tibialis anterior (TA) and slow soleus (SOL) skeletal muscles from 5-month old mKO and control littermates (mean±SEM; n=36/group; ***p<0.001, Student's t-test). (D) Epididymal fat pad weight from 5-month old mKO and control littermates (mean±SEM; n=4/group). (E) Fiber type profile of slow soleus (SOL) and fast extensor digitorum longus (EDL) in transverse sections stained with anti-myosin antibodies specific for type-1/slow (blue), type-2A (green) and type 2B (red) myosin heavy chains. Type 2X fibers are unstained and appear black. Scale bar is 200 µμm. (F) Quantitation of the relative proportion of the different fiber types in SOL and EDL (mean±SEM, n=8 muscles per group with >90% of fibers measured; see methods; *p<0.05, Student's t-test). (G) Hematoxylin and eosin staining of transverse cryosections of SOL muscles from 26-month old mKO and control littermate. Scale bar is 50 µμm. (H) In vivo muscle force measurements performed on gastrocnemius muscles from 5-month old mKO and control littermates. Force normalized to muscle weight (mean±SEM, n=8–10 muscles per group; **p<0.01, ***p<0.001, 2-way ANOVA with Bonferroni correction). (I) Body weight of 7-month old inducible muscle-specific Bmal1 knockout mice (imKO, n=7) and control littermates (Ctrl, n=5) measured 5 months after tamoxifen injections (mean±SEM). (J) Weight of TA and SOL skeletal muscles from 7-month old imKO and control littermates measured 5 months after tamoxifen injections (mean±SEM; n=10–14/group). (K) In vivo muscle force measurements performed on gastrocnemius muscles from 7-month old imKO and control littermates 5 months after tamoxifen injection. Force normalized to muscle weight (mean±SEM, n=8–10 muscles per group).CC BY-NC-SA · PubMed Central
Figure 2 Altered gene expression caused by skeletal muscle-specific Bmal1 knockout. (A) Circadian expression profiles of core clock and clock-associated genes in TA muscles from control and mKO mice. Transcript levels were determined by microarray analysis and plotted as mean absolute expression levels (mean±SEM; n=3/group/timepoint). (B) Phase map of differentially expressed genes in control and mKO skeletal muscles (TA and SOL) identified by maSigPro (see Section 2). Muscles were collected at 4-h intervals throughout the light (ZT0-ZT8, white box) and dark phase (ZT12–ZT20, black box) and hybridized to Affymetrix arrays as described in the methods (n=3/group/timepoint).
Figure 2 Altered gene expression caused by skeletal muscle-specific Bmal1 knockout. (A) Circadian expression profiles of core clock and clock-associated genes in TA muscles from control and mKO mice. Transcript levels were determined by microarray analysis and plotted as mean absolute expression levels (mean±SEM; n=3/group/timepoint). (B) Phase map of differentially expressed genes in control and mKO skeletal muscles (TA and SOL) identified by maSigPro (see Section 2). Muscles were collected at 4-h intervals throughout the light (ZT0-ZT8, white box) and dark phase (ZT12–ZT20, black box) and hybridized to Affymetrix arrays as described in the methods (n=3/group/timepoint).CC BY-NC-SA · PubMed Central
Figure 3 Insulin-dependent glucose uptake is impaired by muscle-specific Bmal1 deletion. (A) Insulin-stimulated [3H]-2-Deoxyglucose (2-DG) uptake by isolated SOL muscles from mKO (left panel) and imKO mice (right panel) versus respective controls (mean±SEM; n=15/group; **p<0.01, ***p<0.001, Student's t-test). (B) Fasting blood glucose levels at ZT0 (n=6/group) and ZT12 (n=10/group) from Ctrl and mKO mice (mean±SEM). (C) Glucose tolerance test performed at ZT12 in mKO mice versus control (mean±SEM; n=10/group). (D) Insulin tolerance test performed at ZT12 in mKO mice versus control (mean±SEM; n=8/group). (E) Basal (−) and insulin-induced (+) AKT Ser473 and Thr308 phosphorylation determined in isolated SOL muscles from mKO and Ctrl mice. (F) In situ diurnal AKT Ser473 phosphorylation (n=5/group/timepoint) and Thr308 phosphorylation (n=3/group/timepoint) in mKO and Ctrl gastrocnemius muscle quantified by densitometry after western blotting analysis (mean±SEM; arbitrary units; AKT Ser473 time effect F=2.88, p=0.02, 2-way ANOVA). (G) Western blots showing protein levels of GLUT4 across the day/night cycle in mKO and Ctrl gastrocnemius muscles from 36 different mice (n=3/group/timepoint). (H) Diurnal protein levels of GLUT4 quantified by densitometry after western blot analysis (mean±SEM; arbitrary units; n=5/group/timepoint; *p<0.05, ***p<0.001, 2-way ANOVA with Bonferroni correction, group effect F=32.2, p<0.0001; time effect F=4.45, p=0.002; group×time interaction F=2.64, p=0.03). Right panel shows mean 24-h GLUT4 protein levels (mean±SEM; arbitrary units; n=30/group; ***p<0.0001, Student's t-test). (I) Western blots showing protein levels of HK2 across the day/night cycle in mKO and Ctrl gastrocnemius muscles from 36 different mice (n=3/group/timepoint). (J) Diurnal protein levels of HK2 quantified by densitometry after western blot analysis (mean±SEM; arbitrary units; n=3/group/timepoint; *p<0.05, **p<0.01, 2-way ANOVA with the Bonferroni correction, group effect F=57.8, p<0.0001). Right panel shows mean 24-h HK2 protein levels (mean±SEM; arbitrary units; n=18/group; ***p<0.0001, Student's t-test). (K) and (L) Diurnal expression profiles of Tbc1d4 (K) and Tbc1d1 (L) transcripts in SOL and TA muscles from Ctrl and mKO mice detected by qPCR and plotted relative to 36B4 expression (mean±SEM; n=3/timepoint; **p<0.01, ***p<0.001, 2-way ANOVA with the Bonferroni correction). (M) Western blots showing TBC1D1 protein levels at three time points in mKO and Ctrl TA muscles. (N) Mean 24-h TBC1D1 protein levels in mKO and Ctrl TA muscles (mean±SEM; arbitrary units; n=4/group; **p<0.01, Student's t-test).
Figure 3 Insulin-dependent glucose uptake is impaired by muscle-specific Bmal1 deletion. (A) Insulin-stimulated [3H]-2-Deoxyglucose (2-DG) uptake by isolated SOL muscles from mKO (left panel) and imKO mice (right panel) versus respective controls (mean±SEM; n=15/group; **p<0.01, ***p<0.001, Student's t-test). (B) Fasting blood glucose levels at ZT0 (n=6/group) and ZT12 (n=10/group) from Ctrl and mKO mice (mean±SEM). (C) Glucose tolerance test performed at ZT12 in mKO mice versus control (mean±SEM; n=10/group). (D) Insulin tolerance test performed at ZT12 in mKO mice versus control (mean±SEM; n=8/group). (E) Basal (−) and insulin-induced (+) AKT Ser473 and Thr308 phosphorylation determined in isolated SOL muscles from mKO and Ctrl mice. (F) In situ diurnal AKT Ser473 phosphorylation (n=5/group/timepoint) and Thr308 phosphorylation (n=3/group/timepoint) in mKO and Ctrl gastrocnemius muscle quantified by densitometry after western blotting analysis (mean±SEM; arbitrary units; AKT Ser473 time effect F=2.88, p=0.02, 2-way ANOVA). (G) Western blots showing protein levels of GLUT4 across the day/night cycle in mKO and Ctrl gastrocnemius muscles from 36 different mice (n=3/group/timepoint). (H) Diurnal protein levels of GLUT4 quantified by densitometry after western blot analysis (mean±SEM; arbitrary units; n=5/group/timepoint; *p<0.05, ***p<0.001, 2-way ANOVA with Bonferroni correction, group effect F=32.2, p<0.0001; time effect F=4.45, p=0.002; group×time interaction F=2.64, p=0.03). Right panel shows mean 24-h GLUT4 protein levels (mean±SEM; arbitrary units; n=30/group; ***p<0.0001, Student's t-test). (I) Western blots showing protein levels of HK2 across the day/night cycle in mKO and Ctrl gastrocnemius muscles from 36 different mice (n=3/group/timepoint). (J) Diurnal protein levels of HK2 quantified by densitometry after western blot analysis (mean±SEM; arbitrary units; n=3/group/timepoint; *p<0.05, **p<0.01, 2-way ANOVA with the Bonferroni correction, group effect F=57.8, p<0.0001). Right panel shows mean 24-h HK2 protein levels (mean±SEM; arbitrary units; n=18/group; ***p<0.0001, Student's t-test). (K) and (L) Diurnal expression profiles of Tbc1d4 (K) and Tbc1d1 (L) transcripts in SOL and TA muscles from Ctrl and mKO mice detected by qPCR and plotted relative to 36B4 expression (mean±SEM; n=3/timepoint; **p<0.01, ***p<0.001, 2-way ANOVA with the Bonferroni correction). (M) Western blots showing TBC1D1 protein levels at three time points in mKO and Ctrl TA muscles. (N) Mean 24-h TBC1D1 protein levels in mKO and Ctrl TA muscles (mean±SEM; arbitrary units; n=4/group; **p<0.01, Student's t-test).CC BY-NC-SA · PubMed Central
Figure 4 Altered sugar metabolites in skeletal muscles from Bmal1 mKO mice. (A) Diurnal variations of glycolytic metabolites in control (Ctrl) and mKO TA muscles (mean±SEM; n=5/group/timepoint; *p<0.05, repeated measures ANOVA). (B) Diurnal changes of other sugar metabolites in Ctrl and mKO TA muscles (mean±SEM; n=5/group/timepoint; *p<0.05, repeated measures ANOVA; see Table S1).
Figure 4 Altered sugar metabolites in skeletal muscles from Bmal1 mKO mice. (A) Diurnal variations of glycolytic metabolites in control (Ctrl) and mKO TA muscles (mean±SEM; n=5/group/timepoint; *p<0.05, repeated measures ANOVA). (B) Diurnal changes of other sugar metabolites in Ctrl and mKO TA muscles (mean±SEM; n=5/group/timepoint; *p<0.05, repeated measures ANOVA; see Table S1).CC BY-NC-SA · PubMed Central
Figure 5 Altered glucose metabolism in skeletal muscles from Bmal1 mKO mice. (A) Glucose oxidation to CO2 measured in isolated diaphragms incubated with 5 mM [1-14C]-glucose at ZT12, at the light/dark transition (mean±SEM; n=5–10/group; *p<0.05, **p<0.01, Student's t-test). (B)–(D) Active pyruvate dehydrogenase (PDHa) activity and PDH phosphorylation in gastrocnemius muscles from Ctrl and mKO mice. (B) Diurnal pattern of PDHa activity. Data are expressed as mmoles/min/kg wet weight (mean±SEM; n=3/group/timepoint; 2-way ANOVA group effect F=6.66, p=0.016). Right panel shows mean 24-h PDHa activity in muscles from Ctrl and mKO mice (mean percent relative to control±SEM; n=18/group; *p<0.05, Student's t-test). (C) Mean 24-h PDHa activity in muscles from Ctrl (n=13) and imKO mice (n=16) (mean percent relative to control±SEM; *p<0.05, Student's t-test). (D) Diurnal PDH-E1α Ser300 phosphorylation quantified by densitometry after western blot analysis in muscles across the diurnal cycle (normalized to total PDH-E1α protein; mean±SEM; arbitrary units; n=3/group/timepoint; 2-way ANOVA group effect F=6.58, p=0.0173). Right panel shows mean 24-h PDH-E1α Ser300 phosphorylation in mKO and control muscles (mean±SEM; arbitrary units; n=18/group; **p<0.01, Student's t-test). (E) Diurnal gene expression profiles of PDH kinase 4 (Pdk4) in Ctrl and mKO TA and SOL muscles detected by qPCR and plotted relative to 36B4 expression (mean±SEM; n=3/group/timepoint; *p<0.05, 2-way ANOVA with the Bonferroni correction). (F) PDK4 protein levels in Ctrl and mKO muscles (gastrocnemius) immediately before and during the dark/active phase (average of values measured at ZT8, 12, 16 and 20) (mean±SEM; n=12; *p<0.05, Student's t-test). (G) Diurnal gene expression profiles of PDH phosphatase 1 (Pdp1) in Ctrl and mKO TA and SOL muscles detected by qPCR and plotted relative to 36B4 expression (mean±SEM; n=3/group/timepoint; *p<0.05, **p<0.01, ***p<0.001, 2-way ANOVA with the Bonferroni correction). (H) Western blots showing PDP1 protein levels, as measured immediately before and during the dark/active phase, in mKO and Ctrl gastrocnemius muscles. (I) PDP1 protein levels in mKO and Ctrl muscles (gastrocnemius) immediately before and during the dark/active phase (ZT8-20; mean±SEM; arbitrary units; n=4/group; **p<0.01, Student's t-test).
Figure 5 Altered glucose metabolism in skeletal muscles from Bmal1 mKO mice. (A) Glucose oxidation to CO2 measured in isolated diaphragms incubated with 5 mM [1-14C]-glucose at ZT12, at the light/dark transition (mean±SEM; n=5–10/group; *p<0.05, **p<0.01, Student's t-test). (B)–(D) Active pyruvate dehydrogenase (PDHa) activity and PDH phosphorylation in gastrocnemius muscles from Ctrl and mKO mice. (B) Diurnal pattern of PDHa activity. Data are expressed as mmoles/min/kg wet weight (mean±SEM; n=3/group/timepoint; 2-way ANOVA group effect F=6.66, p=0.016). Right panel shows mean 24-h PDHa activity in muscles from Ctrl and mKO mice (mean percent relative to control±SEM; n=18/group; *p<0.05, Student's t-test). (C) Mean 24-h PDHa activity in muscles from Ctrl (n=13) and imKO mice (n=16) (mean percent relative to control±SEM; *p<0.05, Student's t-test). (D) Diurnal PDH-E1α Ser300 phosphorylation quantified by densitometry after western blot analysis in muscles across the diurnal cycle (normalized to total PDH-E1α protein; mean±SEM; arbitrary units; n=3/group/timepoint; 2-way ANOVA group effect F=6.58, p=0.0173). Right panel shows mean 24-h PDH-E1α Ser300 phosphorylation in mKO and control muscles (mean±SEM; arbitrary units; n=18/group; **p<0.01, Student's t-test). (E) Diurnal gene expression profiles of PDH kinase 4 (Pdk4) in Ctrl and mKO TA and SOL muscles detected by qPCR and plotted relative to 36B4 expression (mean±SEM; n=3/group/timepoint; *p<0.05, 2-way ANOVA with the Bonferroni correction). (F) PDK4 protein levels in Ctrl and mKO muscles (gastrocnemius) immediately before and during the dark/active phase (average of values measured at ZT8, 12, 16 and 20) (mean±SEM; n=12; *p<0.05, Student's t-test). (G) Diurnal gene expression profiles of PDH phosphatase 1 (Pdp1) in Ctrl and mKO TA and SOL muscles detected by qPCR and plotted relative to 36B4 expression (mean±SEM; n=3/group/timepoint; *p<0.05, **p<0.01, ***p<0.001, 2-way ANOVA with the Bonferroni correction). (H) Western blots showing PDP1 protein levels, as measured immediately before and during the dark/active phase, in mKO and Ctrl gastrocnemius muscles. (I) PDP1 protein levels in mKO and Ctrl muscles (gastrocnemius) immediately before and during the dark/active phase (ZT8-20; mean±SEM; arbitrary units; n=4/group; **p<0.01, Student's t-test).CC BY-NC-SA · PubMed Central
Figure 6 Glucose metabolism in skeletal muscles of Bmal1 mKO mice. In control mice glucose uptake is normally enhanced by insulin at the transition from the rest/fasting to the active/feeding phase, and PDH activity is increased by upregulation of PDP1 and downregulation of PDK4. In Bmal1 mKO mice, insulin-dependent glucose uptake is impaired due to decreased GLUT4 and TBC1D1 protein levels. As a result of reduced HK2 and PDHa activity, glucose metabolism is channeled to alternative pathways, including the polyol, pentose phosphate and glucuronic acid pathways.
Figure 6 Glucose metabolism in skeletal muscles of Bmal1 mKO mice. In control mice glucose uptake is normally enhanced by insulin at the transition from the rest/fasting to the active/feeding phase, and PDH activity is increased by upregulation of PDP1 and downregulation of PDK4. In Bmal1 mKO mice, insulin-dependent glucose uptake is impaired due to decreased GLUT4 and TBC1D1 protein levels. As a result of reduced HK2 and PDHa activity, glucose metabolism is channeled to alternative pathways, including the polyol, pentose phosphate and glucuronic acid pathways.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 73 references

Cited by

Sorted by citations

See all 458

Related

Metadata

Authors
Dyar, K. A., Ciciliot, S., Wright, L. E., Biensø, R. S., Tagliazucchi, G. M., Patel, V. R., Forcato, M., Paz, M. I. P., Gudiksen, A., Solagna, F., Albiero, M., Moretti, I., Eckel-Mahan, K. L., Baldi, P., Sassone-Corsi, P., Rizzuto, R., Bicciato, S., Pilegaard, H., Blaauw, B., & Schiaffino, S.
Affiliations
  • Veneto Institute of Molecular Medicine (IT)
  • University of Padua (IT)
  • University of Copenhagen (DK)
  • University of Modena and Reggio Emilia (IT)
  • University of California, Irvine (US)
Corresponding author
  • Dyar, Kenneth A.
  • Schiaffino, Stefano
ORCID
Venue
Molecular Metabolism
Publisher
Elsevier BV
Published
2014-02
Volume
3
Issue
1
Pages
29-41
ISSN
2212-8778 (ISSN-L)
DOI
10.1016/j.molmet.2013.10.005
PMC
PMC3929910
OpenAlex
W1964634897
Cited by
454
References
73
Citations by year
2026: 34 · 2025: 37 · 2024: 40 · 2023: 46 · 2022: 42 · 2021: 33 · 2020: 53 · 2019: 34 · 2018: 36 · 2017: 28 · 2016: 42 · 2015: 19 · 2014: 9
FWCI
12.78
Type
journal article
Language
en
Update notices
erratum (2014-12-01)
Open access
Licence
Locations
  • Molecular Metabolism (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by-nc-sa)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
  • European Commission (223576, 294777)
  • Italian Space Agency (ASI, project OSMA)
  • Italian Ministries of Health (Ricerca Finalizzata) and of Education, University and Research (PRIN, FIRB), NIA (2P01AG025532-06A1)
  • Cariparo Foundation (Padua)
  • Italian Association for Cancer Research (AIRC) and Telethon–Italy (GPP1005A, GGP11082)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
Keywords
circadian rhythm, Bmal1, insulin sensitivity, glucose uptake, GLUT4, TBC1D1, pyruvate dehydrogenase, PDK4, PDP1, glucose oxidation, glycolysis, metabolome, conditional knockout mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review